Embecta (EMBC) Non-Current Deferred Tax Liability (2021 - 2026)
Embecta (EMBC) reported Non-Current Deferred Tax Liability of $63.4 million for Q1 2026, up 8.38% on a YoY basis from $58.5 million in Q1 2025, and up 3.93% sequentially from $61.0 million in Q4 2025.
Embecta (EMBC) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Embecta (EMBC) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $63.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 8.38% year-over-year to $63.4 million; the trailing twelve-month figure through Mar 2026 stood at $63.4 million (up 8.38% YoY), and the FY2025 full-year result was $62.6 million, up 15.71% from the prior year.
- Non-Current Deferred Tax Liability rose to $63.4 million in Q1 2026, from $61.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $63.5 million in Q2 2025 to a low of $31.4 million in Q1 2022.
- A 5-year average of $50.3 million and a median of $54.1 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability soared 82.28% in 2023 and declined 22.81% in 2024, its largest moves.
- Tracing EMBC's Non-Current Deferred Tax Liability over 5 years: stood at $33.3 million in 2022, then surged by 82.28% to $60.7 million in 2023, then decreased by 8.4% to $55.6 million in 2024, then grew by 9.71% to $61.0 million in 2025, then increased by 3.93% to $63.4 million in 2026.
- Business Quant data shows EMBC's Non-Current Deferred Tax Liability at $63.4 million in Q1 2026, $61.0 million in Q4 2025, and $62.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn |
| 10 | Embecta | 192.72 Mn | -678,250.00 | 127.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.40 Mn |
| Mar 31, 2026 | 63.40 Mn |
| Dec 31, 2025 | 61.00 Mn |
| Dec 31, 2025 | 61.00 Mn |
| Sep 30, 2025 | 62.60 Mn |
| Sep 30, 2025 | 62.60 Mn |
| Jun 30, 2025 | 63.50 Mn |
| Jun 30, 2025 | 63.50 Mn |
| Mar 31, 2025 | 58.50 Mn |
| Mar 31, 2025 | 58.50 Mn |
| Dec 31, 2024 | 55.60 Mn |
| Dec 31, 2024 | 55.60 Mn |
| Sep 30, 2024 | 54.10 Mn |
| Sep 30, 2024 | 54.10 Mn |
| Jun 30, 2024 | 39.20 Mn |
| Jun 30, 2024 | 39.20 Mn |
| Mar 31, 2024 | 36.20 Mn |
| Mar 31, 2024 | 36.20 Mn |
| Dec 31, 2023 | 60.70 Mn |
| Dec 31, 2023 | 60.70 Mn |